AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17209189 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multiple-micronutrient foodLET providing twice the RNI (WMM)
Number of subjects: 133
Study 17209189 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 10-mg Fe foodLET (DI)
Number of subjects: 133
Study 17209189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 15612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-based coping training (CanCOPE)
Number of subjects: 94
Study 15612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coping training for the woman
Number of subjects: 94
Study 15612858 — intervention group
Group type: COMPARATOR
Intervention: Medical education control
Number of subjects: 94
Study 11531839 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.05 mg g(‐1) cream applied 1 hour before PUVA treatment
Number of subjects: 35
Study 11531839 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 1 hour before PUVA treatment
Number of subjects: 35
Study 8155441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐Accelograph (M‐A)
Number of subjects: 0
Study 8155441 — intervention group
Group type: COMPARATOR
Intervention: Myograph 2000 (MYO)
Number of subjects: 0
Study 3147186 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 24
Study 3147186 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (euthyroids)
Number of subjects: 24
Study 3147186 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole-induced euthyroidism
Number of subjects: 24
Study 30247010 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book containing information tailored to their disease/injury plus standard consent discussion
Number of subjects: 38
Study 30247010 — intervention group
Group type: COMPARATOR
Intervention: standard consent discussion
Number of subjects: 38
Study 28397079 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 28397079 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 28397079 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 25482999 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received four in-service workshops and five individualized classroom coaching sessions)
Number of subjects: 32
Study 25482999 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (received only the workshops)
Number of subjects: 32
Study 23474211 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 61
Study 23474211 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise
Number of subjects: 61
Study 23474211 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 61
Study 21640964 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in transobturator tape
Number of subjects: 83
Study 21640964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out transobturator tape
Number of subjects: 83
Study 21640964 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (outside-in and inside-out)
Number of subjects: 83
Study 18845967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg x d(‐1)
Number of subjects: 14
Study 18845967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16412037 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional interventional chemotherapy (infused directly into the common hepatic artery)
Number of subjects: 140
Study 16412037 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (via peripheral vein)
Number of subjects: 140
Study 12667511 — intervention group
Group type: EXPERIMENTAL
Intervention: Music exercise group
Number of subjects: 60
Study 12667511 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy group
Number of subjects: 60
Study 12667511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 10892682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (supercooled tonsillar fossa to between -20 degrees C and -32 degrees C for 1 minute)
Number of subjects: 59
Study 10892682 — intervention group
Group type: COMPARATOR
Intervention: Control (standard post-tonsillectomy care)
Number of subjects: 59
Study 10892682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 59
Study 10892682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 9243241 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of provoking foods
Number of subjects: 15
Study 9243241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of provoking foods
Number of subjects: 15
Study 8216438 — intervention group
Group type: EXPERIMENTAL
Intervention: LNC‐834 (350 mg of hydrated salt corresponding to 226 mg anhydrous free base each) administered twice daily for 9 days, with warfarin (0.36 +/- 0.03 mg/kg) on the 4th day
Number of subjects: 10
Study 8216438 — intervention group
Group type: COMPARATOR
Intervention: Warfarin only (control group)
Number of subjects: 10
Study 3303905 — intervention group
Group type: EXPERIMENTAL
Intervention: FM plus ICRF‐159 (FMI)
Number of subjects: 165
Study 3303905 — intervention group
Group type: EXPERIMENTAL
Intervention: FM plus triazinate (FMT)
Number of subjects: 165
Study 3303905 — intervention group
Group type: COMPARATOR
Intervention: FM plus vincristine (FMV)
Number of subjects: 165
Study 3303905 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 165
Study 31959047 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) supplementation
Number of subjects: 0
Study 31959047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31959047 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) not detected
Number of subjects: 0
Study 28800206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC1)
Number of subjects: 0
Study 28800206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC2)
Number of subjects: 0
Study 28800206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC3)
Number of subjects: 0
Study 28800206 — intervention group
Group type: COMPARATOR
Intervention: Coadministered reference products (1 dutasteride 0.5 mg capsule + 1 tamsulosin hydrochloride 0.2 mg orally disintegrating tablet)
Number of subjects: 0
Study 27299458 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment based on Traditional Chinese Medicine (QLASTCM‐Ga)
Number of subjects: 240
Study 26194172 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1: Health consultations in general practice during a two-year period
Number of subjects: 80
Study 26194172 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2: Educational programme for children and families in addition to health consultations
Number of subjects: 80
Study 24072699 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg daily for week 1 followed by 2000 mg daily for week 2)
Number of subjects: 8
Study 24072699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20495134 — intervention group
Group type: COMPARATOR
Intervention: ABT-107 single oral doses (1, 3, 10, 30, 60, 80, and 100 mg)
Number of subjects: 0
Study 20495134 — intervention group
Group type: COMPARATOR
Intervention: ABT-107 multiple oral doses (2, 6, and 15 mg once daily for 7 days)
Number of subjects: 0
Study 20495134 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-107 20-mg single dose (effect of food)
Number of subjects: 0
Study 20495134 — intervention group
Group type: COMPARATOR
Intervention: Adverse events following single dosing
Number of subjects: 0
Study 20495134 — intervention group
Group type: COMPARATOR
Intervention: Adverse events following multiple dosing
Number of subjects: 0
Study 18209514 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 37
Study 18209514 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 37
Study 16809937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propionyl-L-carnitine (PLC) 600 mg, 3 times weekly for 12 months
Number of subjects: 64
Study 16809937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12842959 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 12842959 — intervention group
Group type: COMPARATOR
Intervention: Current treatment
Number of subjects: 0
Study 10975160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract compomer restoration
Number of subjects: 29
Study 10975160 — intervention group
Group type: COMPARATOR
Intervention: Chemfil Superior glass ionomer restoration
Number of subjects: 29
Study 9208533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 9208533 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 8357293 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychiatric group intervention
Number of subjects: 68
Study 8357293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 3768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 15
Study 3768223 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 15
Study 3768223 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 15
Study 29897821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-repetition/low-load resistance training (20-25 repetitions, 30-50% of 1RM)
Number of subjects: 20
Study 29897821 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-repetition/high-load resistance training (8-12 repetitions, 75-90% of 1RM)
Number of subjects: 20
Study 29231568 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-spreading moxibustion
Number of subjects: 101
Study 29231568 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam (7.5 mg once a day for three days)
Number of subjects: 101
Study 29231568 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 101
Study 25514543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (doses <10 mg/day)
Number of subjects: 39
Study 25514543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22382340 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Arthritis Self-Management Program (ASMP) and self-help book
Number of subjects: 120
Study 22382340 — intervention group
Group type: COMPARATOR
Intervention: Book only (Control)
Number of subjects: 120
Study 20131142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue condition (five bouts of great toe curls at 60% one-repetition maximum to failure)
Number of subjects: 16
Study 20131142 — intervention group
Group type: COMPARATOR
Intervention: Control condition (resting in a supine position for 30 min)
Number of subjects: 16
Study 18311826 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 48
Study 18311826 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 48
Study 18311826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16451371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste brushing after exposure to soft drinks
Number of subjects: 0
Study 16451371 — intervention group
Group type: COMPARATOR
Intervention: Water brushing after exposure to soft drinks
Number of subjects: 0
Study 16451371 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride toothpaste brushing after exposure to soft drinks
Number of subjects: 0
Study 16451371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste slurry after exposure to soft drinks
Number of subjects: 0
Study 16451371 — intervention group
Group type: COMPARATOR
Intervention: Brushing alone (control)
Number of subjects: 0
Study 16451371 — intervention group
Group type: COMPARATOR
Intervention: Soft drinks (OJ, CC, MB) alone
Number of subjects: 0
Study 14575647 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors
Number of subjects: 0
Study 14575647 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 0
Study 14575647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulations of COX-2 inhibitors
Number of subjects: 0
Study 10376693 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of H pylori infection with 14‐day therapy using clarithromycin 500 mg orally 3 times a day and omeprazole 40 mg orally once a day
Number of subjects: 44
Study 10376693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8898601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by psychogeriatric team
Number of subjects: 69
Study 8898601 — intervention group
Group type: COMPARATOR
Intervention: Normal general practitioner care (Control)
Number of subjects: 69
Study 2005681 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ treatment (23 patients)
Number of subjects: 64
Study 2005681 — intervention group
Group type: COMPARATOR
Intervention: Prophylactically inserted stent (41 patients)
Number of subjects: 64
Study 6469442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract 600 mg
Number of subjects: 8
Study 6469442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31425803 — intervention group
Group type: EXPERIMENTAL
Intervention: DATLS (double adaptive threshold level set method)
Number of subjects: 283
Study 31425803 — intervention group
Group type: EXPERIMENTAL
Intervention: DATLS
Number of subjects: 283
Study 30021073 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction
Number of subjects: 120
Study 30021073 — intervention group
Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction
Number of subjects: 120
Study 27010424 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 115
Study 27010424 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HC) diet
Number of subjects: 115
Study 24499405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to promote walking
Number of subjects: 315
Study 22442673 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralised and specialised outpatient intervention program
Number of subjects: 268
Study 22442673 — intervention group
Group type: COMPARATOR
Intervention: Standard decentralised psychiatric treatment
Number of subjects: 268
Study 19995098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg + moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, atorvastatin 40 mg)
Number of subjects: 310
Study 19995098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid + moderate-dose statin
Number of subjects: 310
Study 18376348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.5-1.5 mg/kg/d)
Number of subjects: 28
Study 18376348 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 28
Study 16045525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg, followed by 400 microg)
Number of subjects: 340
Study 16045525 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg, followed by 400 microg)
Number of subjects: 340
Study 12477581 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg IV (Group D)
Number of subjects: 64
Study 12477581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of droperidol 1.25 mg IV and ondansetron 4 mg IV (Group D+O)
Number of subjects: 64
Study 12477581 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Droperidol alone)
Number of subjects: 64
Study 12477581 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Combination of droperidol and ondansetron)
Number of subjects: 64
Study 10072695 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for performance in the perception task
Number of subjects: 0
Study 10072695 — intervention group
Group type: COMPARATOR
Intervention: No performance incentives (Control condition)
Number of subjects: 0
Study 8835555 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 52
Study 8835555 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 52
Study 2326302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope dilution analysis of urinary acylglycines
Number of subjects: 0
Study 2326302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope dilution analysis
Number of subjects: 0
Study 7135113 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine solution (5 mg caffeine/kg body weight) ingested 1 hour prior to running
Number of subjects: 5
Study 7135113 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free drink (control group)
Number of subjects: 5
Study 7135113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (caffeine and control)
Number of subjects: 5
Study 30709370 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 50
Study 30709370 — intervention group
Group type: COMPARATOR
Intervention: Preventive oral care protocol
Number of subjects: 50
Study 27723261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) in addition to usual treatment
Number of subjects: 103
Study 27723261 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment alone (Control)
Number of subjects: 103
Study 26685568 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 232
Study 26685568 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study 23504220 — intervention group
Group type: EXPERIMENTAL
Intervention: Public and professional education intervention
Number of subjects: 0
Study 21837734 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 99
Study 21837734 — intervention group
Group type: COMPARATOR
Intervention: Albumin alone
Number of subjects: 99
Study 21837734 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal of hepatorenal syndrome (HRS)
Number of subjects: 99
Study 21837734 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 99
Study 21837734 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin or albumin alone
Number of subjects: 99
Study 19750959 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical rehabilitation (IPR) consisting of four physical therapy sessions plus three telephone calls
Number of subjects: 50
Study 19750959 — intervention group
Group type: COMPARATOR
Intervention: Group wellness intervention (GWI) consisting of seven educational sessions
Number of subjects: 50
Study 17760283 — intervention group
Group type: EXPERIMENTAL
Intervention: Torso Rotation (TR)
Number of subjects: 25
Study 17760283 — intervention group
Group type: COMPARATOR
Intervention: Supine Head Nodding (HN)
Number of subjects: 25
Study 15209831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatments
Number of subjects: 0
Study 15209831 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant drugs
Number of subjects: 0
Study 11464348 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac rectally every 8 hours (group MD)
Number of subjects: 80
Study 11464348 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g propacetamol intravenously every 6 hours (group MP)
Number of subjects: 80
Study 11464348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 g propacetamol and 100 mg diclofenac (group MDP)
Number of subjects: 80
Study 11464348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group M)
Number of subjects: 80
Study 9521955 — intervention group
Group type: EXPERIMENTAL
Intervention: AMOX/CLAV (40 mg/kg in 3 divided doses daily)
Number of subjects: 0
Study 9521955 — intervention group
Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 0
Study 8041534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy (continuous conjugated equine estrogens at 0.625 mg/day with sequential dl-norgestrel at 0.15 mg/day for 12 days each cycle)
Number of subjects: 61
Study 8041534 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapy (patches delivering continuous 17 beta-estradiol at 0.05 mg/day with sequential norethindrone acetate at 0.25 mg/day for 14 days each cycle)
Number of subjects: 61
Study 8041534 — intervention group
Group type: COMPARATOR
Intervention: Reference group (29 healthy postmenopausal women who did not request therapy)
Number of subjects: 61
Study 2537333 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv) plus placebo hydrocortisone (HC)
Number of subjects: 5
Study 2537333 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv) plus HC
Number of subjects: 5
Study 2537333 — intervention group
Group type: COMPARATOR
Intervention: Placebo oCRH plus HC
Number of subjects: 5
Study 2537333 — intervention group
Group type: COMPARATOR
Intervention: Placebo oCRH plus placebo HC
Number of subjects: 5
Study 2537333 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv)
Number of subjects: 5
Study 2537333 — intervention group
Group type: EXPERIMENTAL
Intervention: HC (variable rate iv infusion)
Number of subjects: 5
Study 1125586 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquine
Number of subjects: 32
Study 1125586 — intervention group
Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 32
Study 1125586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 32
Study 30641096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment continued after meeting switching criteria at month 3
Number of subjects: 1059
Study 30641096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment continued after meeting switching criteria at month 6
Number of subjects: 1059
Study 28741967 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0